Pradeepa Yoganathan Last Word

Related

• 

  Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

  Robert L. Avery, MD

  Updates from the Field

  2021

• 

  What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study

  Roger A. Goldberg, MD, MBA

  Updates from the Field

  2019

• 

  Common Age-Related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Chroma and Spectri Phase 3 Lampalizumab Trials

  Karl G. Csaky, MD, PhD

  Annual Meeting Talks

  2018